IL6 and metastatic neoplasm: Increased serum levels of IL-6 in prostate cancer patients were found to be associated with androgen-independence and metastatic disease (33,34), and overexpression of IL-6 was associated with protection of LNCaP cells from apoptosis during androgen depletion (26).